ICAM1 and melanoma: In addition, an increase in serum levels of soluble ICAM-1 (sICAM-1) has been associated with disease progression, tumor aggressiveness and decreased survival in several malignancies such as melanoma, chronic B-lymphocytic leukemia, lymphoma, and CRC (217–220).